It is critical that partners in clinical research develop systems to maximize the potential of big data while protecting the confidentiality of patient information, to further biomedical research, continued the statement, according to a statement from the European Federation of Pharmaceutical Industries and Associations.
It is critical that partners in clinical research develop systems to maximize the potential of big data while protecting the confidentiality of patient information, to further biomedical research, continued the statement, according to a statement from the European Federation of Pharmaceutical Industries and Associations (EFPIA).
“There is still work to be done. Clinical trials represent on average 58.6% of the total development costs of a new medicine. Across Europe we need to continue to shape the regulatory and clinical landscape putting patient safety at the center and reducing the administrative requirements, speeding up the conduct of clinical trials, while reducing costs. We have to attract patients to participate in trials, provide them with meaningful, jargon-free information and transparent lay summaries of trial results,” stated EFPIA.
To devise meaningful lay summaries, EFPIA is organizing -- together with EFGCP, EPF and EATG, EGAN and Harvard MRCT -- a workshop in Brussels on May 29th, with the aim of embarking on a discussion that will help develop a vision and framework that address stakeholder needs, while increasing transparency and value for public health.
“Looking to the future, clinical trial data will be enhanced by the availability of real world data from patient registries, hospitals and general practitioners. Data will be generated more continuously than ever and have the potential to revolutionize general practice and clinical development. To be able to do so, systems need to adapt for real-time assessment and action,” noted EFPIA.
World Clinical Trials Day, held on May 20th, provided an ideal opportunity to recognize the contribution of the many thousands of trial participants, researchers, companies, sponsors, journals, registries and regulators that have contributed to advances in modern medicine, according to the statement.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.